UCB: stock up, with orphan drug status in US

(CercleFinance.com) - On Wednesday the FDA said that it has granted orphan drug status to fenfluramine hydrochloride, a drug in UCB's portfolio, for the treatment of epileptic seizures.


More specifically, the decision of the US health authority applies to the treatment of CDKL5 deficiency disorder, a rare genetic disease.

This orphan drug designation by the FDA could, amongst other things, enable Zogenix, UCB's subsidiary behind the dossier, to obtain priority review.

This status, which is granted to new treatments for diseases or conditions affecting less than 200,000 people in the US, could also give it seven years of market exclusivity if approved by the FDA.

Following this news, UCB shares were the biggest riser on the BEL 20 index of the Brussels Stock Exchange, up about 2%.


Copyright (c) 2022 CercleFinance.com. All rights reserved.